2415016-05-4 + 749927-69-3 = 956104-40-8 反应条件:1.1 Reagents: N,N,N′,N′-Tetramethylethylenediamine,Potassium Carbonate Catalysts: Cuprous Iodide Solvents: Dimethylformamide; 6 H,110 °C; 110 °C -> Rt1.2 Reagents: Ammonia Solvents: Water; 0.5 H,Rt 标题:Preparation Of Thiodiazaspiro Compound And Its Intermediates 参考文献:China]
915087-26-2 + 951753-87-0 = 956104-40-8 反应条件:1.1 Solvents: Dimethylformamide; 20 H,80 °C1.2 Reagents: Hydrochloric Acid Solvents: Methanol,Water; 2 H 标题:Preparation Of Hydantoins As Androgen Receptor Modulators For The Treatment Of Prostate Cancer And Other Androgen Receptor-Associated Diseases. 参考文献:World Intellectual Property Organization]
573762-62-6 + 102368-13-8 + 2227589-23-1 = 956104-40-8 反应条件:1.1 Solvents: Toluene; 9 - 11 H,90 - 100 °C; 100 °C -> 5 °C; 1 H,5 °C 标题:Preparation Of Apalutamide And An Amorphous Solid Dispersion Containing It 参考文献:World Intellectual Property Organization]
1950587-19-5 = 956104-40-8 反应条件:1.1 Solvents: Tetrahydrofuran,Water; 5 - 15 °C; 16 H,50 °C 标题:Method For Synthesizing Apalutamide As Non-Steroidal Androgen Receptor Inhibitor And Intermediate With High Yield 参考文献:China]
1950587-20-8 + 96989-50-3 = 956104-40-8 反应条件:1.1 Reagents: Diisopropylethylamine Solvents: Toluene; Rt -> 100 °C; 2 H,100 °C; 2 H,95 - 105 °C 标题:Preparation Of Thiodiazepine Spirochetes And Their Intermediates 参考文献:China]
1950587-20-8 + 102368-13-8 = 956104-40-8 反应条件:1.1 Catalysts: 4-(Dimethylamino)Pyridine Solvents: Dimethylacetamide; 2 H,Rt -> 90 °C 标题:Process For The Preparation Of Apalutamide 参考文献:World Intellectual Property Organization]
= 956104-40-8 反应条件:1.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 24 H,Rt1.2 Reagents: Sodium Hydroxide Solvents: Water; Ph 8 - 9,Rt 标题:Method And Intermediate For Synthesizing Apalutamide And Intermediate 参考文献:China]
1950587-19-5 = 956104-40-8 反应条件:1.1 Solvents: Water; 1 H,20 - 30 °C 标题:Preparation Of Apalutamide And Apalutamide Intermediate 参考文献:China]
1950587-19-5 = 956104-40-8 反应条件:1.1 Solvents: Water; Rt; 1 H,20 - 30 °C 标题:Method For Preparing Apalutamide Intermediate And Apalutamide With High Yield 参考文献:China]
951753-87-0 + 2522932-00-7 = 956104-40-8 反应条件:1.1 Solvents: Dimethyl Sulfoxide,Isopropyl Acetate; Rt -> 90 °C; 24 H,90 °C 标题:Preparation Of Benzamide Compound And Its Application In Preparation Of Androgen Receptor Inhibitor (Apalutamide) 参考文献:China]
专利号:US-9926291-B2 优先权日:2007-03-27 标 题 :Synthesis of thiohydantoins 发明人:OUERFELLI OUATHEK; DILHAS ANNA; YANG GUANGBIN; ZHAO HONG 权利人:SLOAN KETTERING INST CANCER RES 摘要:A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
专利号:US-2025268920-A1 优先权日:2022-04-20 标 题:Use of androgen receptor-mediated mechanisms in the treatment of acute myeloid leukemia 发明人:QIAN FENGHUA; PRABHU KUMBLE SANDEEP; PAULSON ROBERT F 权利人:PENN STATE RES FOUND 摘要:Provided is a method for treating a blood cancer in an individual in need thereof by administrating to the individual an agent that inhibits activity or expression of one or more enzymes that participate in synthesis of either or both dihydrotestosterone (DHT) or androgen receptor (AR), or an antagonist AR, or a combination of an agent and the antagonist. The methods are shown in connection with acute myeloid leukemia (AML).
专利号:US-2025289827-A1 优先权日:2022-12-02 标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof 发明人:YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN 权利人:C4 THERAPEUTICS INC 摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.
专利号:US-2022153718-A1 优先权日:2019-03-15 标 题:Synthesis of stable amorphous apalutamide 发明人:GRANDE VALENTINA; NOVO BARBARA; SADA MARA; FERRETTI GABRIELE; MANFREDI ALESSIA 权利人:OLON SPA 摘要:The present invention relates to a process for the preparation of apalutamide in stable amorphous form. The invention also relates to a novel intermediate crystalline form, called form X, which gives rise to said amorphous form, and a process for obtaining said form X.
专利号:US-2023391824-A1 优先权日:2021-02-08 标题:Rationale, design, synthesis and validation of a small molecule anticancer agent 发明人:JAIN MOHIT; NARENDRAN ARUMUGAVADIVEL 权利人:NARENDRAN ARUMUGAVADIVEL 摘要:LIN28 is an RNA binding protein that binds and inhibits the expression and maturation of Iet7 microRNA that carries key tumor suppressor functions. Thus, LIN28 is a feasible and effective molecular target for directed inhibition with the potential to provide therapeutic benefit to a diverse group of aggressive malignancies. The present disclosure relates generally to the Rationale, Design, Synthesis and Validation of a Novel Small Molecule Inhibitor of LIN28, coined Compound of formula (I), for the Treatment of Adult and Pediatric Malignancies. In addition, indications of this agent to block cancer metastasis, inhibit cancer stem cells to prevent relapse, and to synergize with immunotherapy, chemotherapy and radiotherapy are also been described.
专利号:US-2022118123-A1 优先权日:2019-02-22 标 题 :Combination of ar antagonists and targeted thorium conjugates 发明人:HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY 权利人:BAYER AG; BAYER AS 摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.
1: Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. 2: Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. 42(3):354-373. doi: 10.1210/endrev/bnab002. 4: Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021 Jan;79(1):150-158. doi: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6. 39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29. 6(8):702-715. doi: 10.1016/j.trecan.2020.04.010. Epub 2020 Jun 10. SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. 7(1):198. doi: 10.1038/s41392-022-01042-7.
合成参考文献
参考文献:10.1007/s12609-014-0140-5 摘要:Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M. Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. Current Breast Cancer Reports. 2014 Feb 13;6(2):71–8. doi: 10.1007/s12609-014-0140-5. 参考文献:10.1007/s00120-017-0329-0 摘要:Rexer H, Graefen M. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO]. Urologe A. 2017 Feb;56(2):243–4. doi: 10.1007/s00120-017-0329-0.